Drug Monograph
Velcade (Bortezomib)
bortezomib — proteasome inhibitor
Pharmacokinetic Profile
Half-Life
9–15 h (single dose); 40–193 h (repeat dosing)
Protein Binding
83%
Volume of Distribution
~498–1,884 L/m²
Metabolism
CYP3A4, CYP2C19, CYP1A2 (oxidative deboronation)
SC vs IV AUC
Equivalent (ratio 0.99)
Clinical Information
Drug Class
Proteasome inhibitor
Formulation
3.5 mg lyophilised powder per vial
Routes
IV bolus (3–5 sec) or SC injection
Renal Adjustment
Not required (including dialysis)
Hepatic Adjustment
Required (moderate/severe: start 0.7 mg/m²)
Pregnancy
Can cause fetal harm
Lactation
Do not breastfeed during + 2 months after
Generic Available
Yes (multiple generics + Boruzu ready-to-use)
Indications for Bortezomib
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Multiple myeloma — all lines | Adults (previously untreated and relapsed/refractory) | Combination or monotherapy | FDA Approved |
| Mantle cell lymphoma | Adults (previously untreated and relapsed) | Combination (VcR-CAP) or monotherapy | FDA Approved |
Bortezomib was the first proteasome inhibitor approved by the FDA, initially receiving accelerated approval in 2003 for relapsed/refractory multiple myeloma based on the SUMMIT trial. Its indications were subsequently expanded to include previously untreated myeloma (2008, with melphalan-prednisone) and mantle cell lymphoma (2006 relapsed, 2014 frontline with VcR-CAP). Bortezomib is now a cornerstone of multiple myeloma therapy, used across all treatment lines, and forms the backbone of the standard first-line VRd (bortezomib-lenalidomide-dexamethasone) regimen recommended by NCCN guidelines, though VRd-specific dosing is detailed in the lenalidomide and dexamethasone prescribing information rather than the bortezomib PI itself.
Off-Label Uses
Waldenström macroglobulinaemia — bortezomib-based regimens (BDR, BendaR-V). Evidence quality: High (NCCN recommended).
Systemic AL amyloidosis — CyBorD regimen (cyclophosphamide-bortezomib-dexamethasone). Evidence quality: High (standard of care).
Antibody-mediated transplant rejection — as part of desensitisation protocols. Evidence quality: Moderate.
Dosing for Bortezomib
Adult Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Previously untreated MM — with melphalan + prednisone (VMP) | 1.3 mg/m² IV or SC | 1.3 mg/m² | 1.3 mg/m²/dose | Cycles 1–4: twice weekly (Days 1,4,8,11,22,25,29,32 of 42-day cycle); Cycles 5–9: once weekly (Days 1,8,22,29 of 42-day cycle) 9 cycles total; ≥72 h between doses |
| Previously untreated MCL — VcR-CAP | 1.3 mg/m² IV | 1.3 mg/m² | 1.3 mg/m²/dose | Twice weekly Days 1,4,8,11 of 21-day cycle for 6 cycles (up to 8 if responding at Cycle 6) With rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², prednisone 100 mg/m² |
| Relapsed MM or relapsed MCL | 1.3 mg/m² IV or SC | 1.3 mg/m² | 1.3 mg/m²/dose | Twice weekly Days 1,4,8,11 of 21-day cycle for up to 8 cycles; then may switch to once weekly Days 1,8,15,22 of 35-day cycle (MM) ≥72 h between consecutive doses |
| MM retreatment (prior responders, relapsed ≥6 months after prior bortezomib) | Last tolerated dose | As tolerated | 1.3 mg/m²/dose | Twice weekly schedule for up to 8 cycles; may combine with dexamethasone |
| Moderate or severe hepatic impairment | 0.7 mg/m² | Consider escalation to 1.0 mg/m² or reduction to 0.5 mg/m² based on tolerance | 1.0 mg/m²/dose | Moderate: bilirubin >1.5–3× ULN; Severe: bilirubin >3× ULN Mild hepatic impairment: no dose adjustment needed |
Peripheral Neuropathy Dose Modifications
| Neuropathy Grade | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Grade 1 without pain | No change | Continue current dose and schedule | ||
| Grade 1 with pain or Grade 2 | Reduce to 1.0 mg/m² | Continue current schedule | ||
| Grade 2 with pain or Grade 3 | Hold; resume at 0.7 mg/m² once weekly | Wait until toxicity resolves before restarting | ||
| Grade 4 | Discontinue bortezomib | Do not rechallenge | ||
Clinical Pearl: Subcutaneous Administration Reduces Neuropathy
In the Phase 3 SC vs IV study, Grade ≥2 peripheral neuropathy was 24% with subcutaneous versus 39% with intravenous bortezomib, and Grade ≥3 was 6% versus 15% respectively (PI Section 5.1). Starting bortezomib subcutaneously is recommended for patients with pre-existing or high-risk peripheral neuropathy. SC and IV routes provide equivalent systemic exposure (AUC ratio 0.99), making SC the preferred route for most patients in current practice.
Pharmacology of Bortezomib
Mechanism of Action
Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome, a large protein complex responsible for degrading ubiquitinated proteins that regulate cell-cycle progression, apoptosis, and NF-κB signalling. By blocking proteasomal degradation, bortezomib causes accumulation of pro-apoptotic proteins and disrupts NF-κB-dependent survival signals in malignant plasma cells. Maximum proteasome inhibition occurs within five minutes of intravenous dosing and recovers to near baseline within 72–96 hours, providing the pharmacodynamic rationale for the twice-weekly dosing schedule with mandatory ≥72-hour inter-dose intervals. Bortezomib is cytotoxic to myeloma cells in vitro, synergises with dexamethasone and alkylating agents, and can overcome resistance to conventional chemotherapy.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | IV: rapid bolus (3–5 sec); IV Cmax ~112 ng/mL (1.3 mg/m², Day 1). SC: Cmax ~20 ng/mL (lower peak but equivalent AUC; ratio 0.99, 90% CI 0.80–1.23) | SC and IV are interchangeable from an exposure standpoint; SC preferred for neuropathy reduction |
| Distribution | Vd ~498–1,884 L/m²; distributes widely into peripheral tissues; protein binding ~83% (100–1,000 ng/mL) | Very large Vd reflects extensive tissue distribution and proteasome binding; target-mediated drug disposition prolongs terminal half-life with repeat dosing |
| Metabolism | Primarily hepatic via oxidative deboronation by CYP3A4, CYP2C19, and CYP1A2; minor CYP2D6 and CYP2C9; all metabolites inactive; bortezomib may inhibit CYP2C19 | Strong CYP3A4 inducers (rifampin) decrease exposure ~45% — avoid; strong CYP3A4 inhibitors (ketoconazole) increase exposure ~35% — monitor closely; may increase exposure to CYP2C19 substrates |
| Elimination | t½ single dose 9–15 h; with repeat dosing 40–193 h (target-mediated prolongation); elimination pathways not fully characterised in humans | No renal dose adjustment needed (PK unaffected by renal impairment, including dialysis); hepatic impairment increases AUC by ~60% — dose reduction required for moderate/severe HI |
Side Effects of Bortezomib
≥20%Very Common (Relapsed MM: Bortezomib vs Dexamethasone, N=331)
| Adverse Effect | Incidence (Bortezomib Arm) | Clinical Note |
|---|---|---|
| Nausea | 52% | Anti-emetics recommended; usually manageable |
| Diarrhoea | 52% (Grade 3: 7%) | Fluid/electrolyte replacement; anti-diarrhoeal agents as needed |
| Fatigue | 39% (Grade 3: 5%) | Common across all regimens |
| Peripheral neuropathies | 35% (Grade 3: 7%; Grade 4: <1%) | Predominantly sensory; SC reduces risk (Grade ≥2: SC 24% vs IV 39%); dose-modify per Table 5 |
| Thrombocytopenia | 33% (Grade 3: 24%; Grade 4: 4%) | Cyclical: nadir ~40% of baseline at Day 11; recovers before next cycle; non-cumulative |
| Constipation | 30% | May require laxatives; ileus can occur (rare) |
| Vomiting | 29% | Usually manageable with anti-emetics |
| Anorexia | 21% | Monitor weight; nutritional support as needed |
10–20%Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Pyrexia | 20% | Rule out infection, especially febrile neutropenia |
| Paraesthesia | 19% | Part of neuropathy spectrum; use neuropathy dose modification table |
| Anaemia | 19% (Grade 3: 6%) | May require transfusion support |
| Headache | 19% | Usually mild |
| Neutropenia | 18% (Grade 3: 11%; Grade 4: 2%) | Non-cumulative; Grade 4 neutropenia 70% in VcR-CAP for MCL |
| Rash | 13% | Usually mild; assess for herpes zoster |
| Herpes zoster | 11% (VMP) | Antiviral prophylaxis (aciclovir/valaciclovir) strongly recommended |
SeriousSerious Adverse Effects
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe peripheral neuropathy (Grade ≥3) | IV: 15%; SC: 6% | Cumulative with repeat cycles | Hold or discontinue per Table 5; improvement/resolution in 48% after dose adjustment; 73% after discontinuation |
| Severe thrombocytopenia (Grade 3/4) | 24%/4% (relapsed MM); Grade 4: 32% (VcR-CAP MCL) | Cyclical: nadir Day 11, recovers before next cycle | Check platelets before each dose; transfuse per guidelines; dose-adjust for VMP per Table 2 |
| Cardiac toxicity (CHF, decreased LVEF) | 8% treatment-related cardiac disorders | Variable; can occur without risk factors | Frequent monitoring in patients with cardiac disease or risk factors; interrupt bortezomib if cardiac failure develops |
| Hypotension (postural/orthostatic) | 8% | Throughout therapy | Caution with antihypertensives; hydration; may need mineralocorticoids/sympathomimetics |
| Pulmonary toxicity (ARDS, pneumonitis) | Rare; some fatal | Variable | Interrupt bortezomib for new/worsening cardiopulmonary symptoms; comprehensive diagnostic evaluation |
| Posterior reversible encephalopathy syndrome (PRES) | Rare | Variable | Discontinue bortezomib; confirm with MRI; safety of rechallenge unknown |
| Hepatic toxicity (including acute liver failure) | Reported; rare | Variable | Monitor LFTs; interrupt to assess reversibility |
| Thrombotic microangiopathy (TTP/HUS) | Rare; sometimes fatal (post-marketing) | Variable | Stop bortezomib if suspected; evaluate; safety of rechallenge unknown |
| Embryo-fetal toxicity | Post-implantation loss in rabbits at ~0.5× clinical dose | Any exposure during pregnancy | Effective contraception: females during + 7 months after; males during + 4 months after treatment |
DiscontinuationDiscontinuation Rates
Relapsed MM (Bortezomib arm)
25% d/c due to adverse reactions
Most common reason: peripheral neuropathy (8%); 4 bortezomib-related deaths (cardiogenic shock, respiratory insufficiency, CHF, cardiac arrest)
Relapsed MM (Dexamethasone arm)
18% d/c due to adverse reactions
Most common reason: psychotic disorder and hyperglycaemia (2% each)
Herpes Zoster Prophylaxis
Bortezomib carries a high risk of herpes zoster reactivation (11–13% in clinical trials). Antiviral prophylaxis with aciclovir (400 mg twice daily) or valaciclovir (500 mg daily) is strongly recommended for all patients receiving bortezomib, continuing for at least 3 months after treatment completion. This practice has been adopted by NCCN and ESMO guidelines despite not being mandated in the FDA PI.
Drug Interactions with Bortezomib
Bortezomib is metabolised by CYP3A4, CYP2C19, and CYP1A2. It is not an inducer of CYP enzymes but may inhibit CYP2C19. No formal drug-interaction studies were conducted initially, but subsequent controlled studies have characterised the key CYP3A4 interactions.
MajorStrong CYP3A4 Inducers (rifampin, phenytoin, carbamazepine)
MechanismCYP3A4 induction accelerates bortezomib metabolism
EffectRifampin decreased bortezomib exposure by approximately 45%
ManagementAvoid concomitant use (PI Section 7.3)
FDA PIModerateStrong CYP3A4 Inhibitors (ketoconazole)
MechanismCYP3A4 inhibition reduces bortezomib clearance
EffectKetoconazole increased bortezomib exposure by 35%
ManagementMonitor closely for bortezomib toxicity; consider dose reduction if toxicity occurs (PI Section 7.1)
FDA PIModerateCYP2C19 Substrates (e.g. omeprazole, clopidogrel)
MechanismBortezomib may inhibit CYP2C19 activity
EffectMay increase exposure to CYP2C19-metabolised drugs
ManagementMonitor for increased effects/toxicity of CYP2C19 substrates
FDA PIModerateGreen Tea / EGCG
MechanismEGCG directly binds to and blocks the boronic acid moiety of bortezomib
EffectReduces proteasome inhibition and antineoplastic efficacy in vitro
ManagementAdvise patients to avoid green tea supplements during bortezomib treatment
In vitro · LexicompMonitoring for Bortezomib
- CBC with PlateletsBefore each bortezomib dose (especially platelets)
RoutineCyclical thrombocytopenia (nadir Day 11, recovery before next cycle). Non-cumulative. Grade 3/4 thrombocytopenia 28% (relapsed MM). Platelet transfusion per guidelines. - Neuropathy AssessmentBefore each cycle and as symptoms arise
RoutineMonitor for numbness, tingling, burning, pain, weakness. Grade ≥2 neuropathy: SC 24% vs IV 39%. Dose modify per Table 5. Improvement in 48–73% after dose adjustment or discontinuation. - Blood PressureEach treatment day
RoutineOrthostatic hypotension in 8%. Review antihypertensive medications; ensure adequate hydration. - Liver Function TestsPeriodically during treatment
RoutineAcute liver failure reported. Interrupt bortezomib to assess reversibility. Start at 0.7 mg/m² if bilirubin >1.5× ULN. - Blood GlucoseFrequently in diabetic patients
Trigger-basedAntidiabetic medication may require adjustment. Concurrent dexamethasone worsens hyperglycaemia. - Cardiac FunctionAs clinically indicated
Trigger-basedExacerbation of CHF and new-onset LVEF decline reported, including in patients without cardiac risk factors. Closely monitor patients with existing heart disease. - Pregnancy TestingBefore initiation
RoutineEmbryo-fetal toxicity documented. Contraception required: females during + 7 months after; males during + 4 months after treatment.
Contraindications & Cautions for Bortezomib
Absolute Contraindications
- Intrathecal administration — Fatal events have occurred with intrathecal bortezomib. For IV or SC use only (PI Section 4).
- Hypersensitivity to bortezomib, boron, or mannitol — Not including local injection-site reactions. Anaphylactic reactions reported (PI Section 4).
Relative Contraindications (Specialist Input Recommended)
- Pre-existing severe peripheral neuropathy — Use only after careful risk-benefit assessment; consider SC route and lower starting dose (PI Section 2.7).
- Decompensated heart failure or significant cardiac disease — Closely monitor; new-onset CHF and LVEF decline reported even without cardiac risk factors.
Use with Caution
- Moderate or severe hepatic impairment — AUC increased ~60%; start at 0.7 mg/m² (PI Section 2.8).
- Patients taking antihypertensives or with dehydration — Risk of orthostatic hypotension (8%).
- Diabetes mellitus — Blood glucose fluctuations reported; close monitoring and antidiabetic medication adjustment may be needed (PI Section 8.8).
- Patients with high tumour burden — Risk of tumour lysis syndrome.
- Concomitant strong CYP3A4 inducers — Avoid; reduces bortezomib exposure by ~45%.
FDA Class-Wide Safety AdvisoryIntrathecal Administration is Fatal
Bortezomib is contraindicated for intrathecal administration. Fatal events have been reported following inadvertent intrathecal injection. The drug is for intravenous or subcutaneous use ONLY. Stickers indicating the route of administration are provided with each vial and should be placed directly on the syringe once prepared.
Patient Counselling for Bortezomib
Purpose of Therapy
Bortezomib is an injection given under the skin or into a vein that works by blocking a protein-recycling machine inside cancer cells (the proteasome), causing harmful proteins to build up and triggering cancer cell death. It is used to treat multiple myeloma and mantle cell lymphoma, and is often given in combination with other medicines.
How It Is Given
Bortezomib is administered as an injection by a healthcare professional, typically twice weekly for two weeks followed by a rest period. Treatment cycles are repeated according to your treatment plan. The dose is calculated based on your body size.
Numbness, Tingling & Nerve Pain (Peripheral Neuropathy)
Tell patientNumbness, tingling, burning, or pain in the hands or feet is a common side effect and can be long-lasting. It is less common when the drug is given under the skin rather than into a vein. Report any new or worsening symptoms promptly, as early dose adjustment can prevent permanent nerve damage.
Call prescriberFor new or worsening numbness, pain, tingling, burning, or weakness in hands or feet; difficulty with buttons, writing, or walking.
Shingles (Herpes Zoster) Prevention
Tell patientYou are at increased risk of shingles during treatment. You will likely be prescribed an antiviral medication (aciclovir or valaciclovir) to prevent this. Take the antiviral as directed throughout your treatment and for several months after.
Call prescriberFor a painful rash or blisters on one side of the body, especially if spreading near the eyes.
Dizziness & Low Blood Pressure
Tell patientBortezomib can lower blood pressure, causing dizziness especially when standing up quickly. Stay well hydrated, rise slowly from sitting or lying positions, and use caution when driving or operating machinery.
Call prescriberFor fainting, persistent dizziness, or feeling lightheaded despite adequate fluid intake.
Pregnancy Prevention
Tell patientBortezomib can harm an unborn baby. Females should use effective contraception during treatment and for 7 months after the last dose. Males should use contraception during treatment and for 4 months after. Do not breastfeed during treatment or for 2 months after the last dose.
Call prescriberImmediately if pregnancy is suspected.
Sources
Regulatory (PI / SmPC)
- Velcade (bortezomib) for injection. Full Prescribing Information. Takeda Pharmaceutical Company. Revised November 2021. FDA LabelPrimary source for all dosing regimens, dose modifications, adverse reactions, PK data, and warnings in this monograph.
Key Clinical Trials
- San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (VISTA). N Engl J Med. 2008;359(9):906-917. doi:10.1056/NEJMoa0801479VISTA trial establishing VMP as standard first-line treatment for transplant-ineligible NDMM patients.
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (APEX). N Engl J Med. 2005;352(24):2487-2498. doi:10.1056/NEJMoa043445Phase 3 APEX trial demonstrating superiority of bortezomib over dexamethasone in relapsed MM (TTP 6.2 vs 3.5 months; 1-year survival 80% vs 66%).
- Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma (LYM-3002). N Engl J Med. 2015;372(10):944-953. doi:10.1056/NEJMoa1412096LYM-3002 trial establishing VcR-CAP as standard frontline treatment for MCL, showing superior PFS over R-CHOP.
- Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Lancet Oncol. 2011;12(5):431-440. doi:10.1016/S1470-2045(11)70081-XPhase 3 trial demonstrating equivalent efficacy of SC vs IV bortezomib with significantly lower neuropathy rates (Grade ≥2: 24% vs 39%).
- Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma (SWOG S0777). Lancet. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-XSWOG S0777 establishing VRd as the preferred first-line regimen for newly diagnosed MM, demonstrating PFS and OS benefit over Rd alone.
Guidelines
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Multiple Myeloma. Version 5.2024. NCCNCurrent NCCN guidelines designating VRd as a Category 1 preferred first-line regimen for NDMM.
Mechanistic / Basic Science
- Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615-2622. PMID: 10363983Foundational paper describing the rationale and early preclinical development of bortezomib as a proteasome inhibitor.
Pharmacokinetics / Special Populations
- Reece DE, Sullivan D, Lonial S, et al. Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother Pharmacol. 2011;67(1):57-67. doi:10.1007/s00280-010-1283-3PK/PD study at 1.0 and 1.3 mg/m² documenting decreased clearance and increased half-life with repeat dosing.
- Bross PF, Kane R, Farrell AT, et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res. 2004;10(12 Pt 1):3954-3964. doi:10.1158/1078-0432.CCR-03-0781FDA approval summary documenting the clinical and pharmacological basis for the initial accelerated approval of bortezomib.
- Moreau P, Karamanesht II, Domnikova N, et al. Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012;51(12):823-829. doi:10.1007/s40262-012-0010-0PK analysis confirming bioequivalence of SC and IV bortezomib (AUC ratio 0.99) with lower Cmax for SC (20.4 vs 223 ng/mL).